Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives Consensus Recommendation of "Hold" from Analysts

Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) has been assigned an average rating of "Hold" from the five research firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, one has assigned a hold rating and two have issued a buy rating on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $80.00.

MCRB has been the subject of several recent analyst reports. Chardan Capital restated a "buy" rating and issued a $25.00 price target on shares of Seres Therapeutics in a research note on Thursday, March 20th. The Goldman Sachs Group cut their target price on shares of Seres Therapeutics from $20.00 to $15.00 and set a "sell" rating for the company in a research note on Friday, March 14th. Finally, StockNews.com cut shares of Seres Therapeutics from a "hold" rating to a "sell" rating in a research note on Thursday, May 1st.

Seres Therapeutics Trading Down 7.4 %

MCRB stock traded down $0.68 during midday trading on Friday, reaching $8.55. 83,099 shares of the company's stock traded hands, compared to its average volume of 155,065. The stock has a market cap of $74.54 million, a P/E ratio of -37.17 and a beta of 2.89. The stock's 50-day moving average is $12.22 and its 200 day moving average is $14.87. Seres Therapeutics has a 52-week low of $7.18 and a 52-week high of $30.60.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of MCRB. State Street Corp grew its position in Seres Therapeutics by 12.9% during the third quarter. State Street Corp now owns 383,248 shares of the biotechnology company's stock valued at $363,000 after buying an additional 43,700 shares during the period. Geode Capital Management LLC lifted its stake in Seres Therapeutics by 22.5% in the 3rd quarter. Geode Capital Management LLC now owns 1,388,639 shares of the biotechnology company's stock valued at $1,314,000 after buying an additional 255,014 shares in the last quarter. Virtu Financial LLC boosted its stake in shares of Seres Therapeutics by 44.8% in the third quarter. Virtu Financial LLC now owns 58,791 shares of the biotechnology company's stock worth $56,000 after acquiring an additional 18,191 shares during the last quarter. Vontobel Holding Ltd. raised its position in shares of Seres Therapeutics by 137.6% in the fourth quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company's stock valued at $780,000 after buying an additional 543,469 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its stake in Seres Therapeutics by 15.6% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company's stock worth $720,000 after purchasing an additional 117,107 shares in the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.